核受体
过氧化物酶体增殖物激活受体
炎症
PPAR激动剂
药品
脂质代谢
受体
内分泌学
药物开发
药理学
生物
过氧化物酶体增殖物激活受体α
过氧化物酶体
生物信息学
生物化学
免疫学
转录因子
基因
作者
Nadia Bougarne,Basiel Weyers,Sofie Desmet,Julie Deckers,David Ray,Bart Staels,Karolien De Bosscher
出处
期刊:Endocrine Reviews
[The Endocrine Society]
日期:2018-07-17
卷期号:39 (5): 760-802
被引量:481
标识
DOI:10.1210/er.2018-00064
摘要
Peroxisome proliferator-activated receptor α (PPARα) is a nuclear receptor of clinical interest as a drug target in various metabolic disorders. PPARα also exhibits marked anti-inflammatory capacities. The first-generation PPARα agonists, the fibrates, have however been hampered by drug-drug interaction issues, statin drop-in, and ill-designed cardiovascular intervention trials. Notwithstanding, understanding the molecular mechanisms by which PPARα works will enable control of its activities as a drug target for metabolic diseases with an underlying inflammatory component. Given its role in reshaping the immune system, the full potential of this nuclear receptor subtype as a versatile drug target with high plasticity becomes increasingly clear, and a novel generation of agonists may pave the way for novel fields of applications.
科研通智能强力驱动
Strongly Powered by AbleSci AI